Cel-Sci Corporation (CVM) Financial Statements (2023 and earlier)

Company Profile

Business Address 8229 BOONE BLVD .
VIENNA, VA 22182
State of Incorp. CO
Fiscal Year End September 30
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2022
12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments22,67237,11042,21215,5098,44510,310
Cash and cash equivalents22,67237,11036,06015,5098,44510,310
Short-term investments  6,151   
Receivables 55555563119
Inventory, net of allowances, customer advances and progress billings2,002 2,007820782645
Inventory2,002 2,007820782645
Prepaid expense7627249981,313525365
Other undisclosed current assets 3,979    
Total current assets:25,43641,86745,27217,6979,81511,439
Noncurrent Assets
Inventory, Noncurrent164     
Finance lease, right-of-use asset10,93812,25312,69213,812 
Operating lease, right-of-use asset1,8842,0142,0561,199 
Property, plant and equipment11,88913,29013,6645,84415,82616,219
Intangible assets, net (including goodwill)212 276313312258
Intangible assets, net (excluding goodwill)212 276313312258
Other undisclosed noncurrent assets 2481,911(19,468)1,6711,671
Total noncurrent assets:25,08827,80430,5981,70017,80818,148
Other undisclosed assets   21,139  
TOTAL ASSETS:50,52469,67275,87040,53627,62329,586
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,4612,0932,5352,5341,6215,949
Accounts payable1,6181,1931,6762,0231,5865,744
Accrued liabilities84290085951134205
Derivative instruments and hedges, liabilities 24372146742,499
Due to related parties471475266448709765
Other liabilities    1514
Other undisclosed current liabilities1,7317646991,070  
Total current liabilities:4,6643,3333,9374,2663,0209,227
Noncurrent Liabilities
Long-term debt and lease obligation13,57214,86215,27412,867  
Finance lease, liability11,72112,88013,25211,753 
Operating lease, liability1,8501,9812,0211,114 
Liabilities, other than long-term debt1251251253,6775,8366,852
Other liabilities1251251251252333
Derivative instruments and hedges, liabilities   3,5525,8146,818
Other undisclosed noncurrent liabilities    13,63313,507
Total noncurrent liabilities:13,69714,98715,39916,54419,47020,359
Total liabilities:18,36018,32019,33620,81022,48929,586
Stockholders' equity
Stockholders' equity attributable to parent32,16351,35156,53419,7275,1341
Common stock434433432387352280
Additional paid in capital486,626477,898474,299401,175358,508331,312
Accumulated deficit(454,897)(426,979)(418,196)(381,835)(353,726)(331,592)
Total stockholders' equity:32,16351,35156,53419,7275,1341
TOTAL LIABILITIES AND EQUITY:50,52469,67275,87040,53627,62329,586

Income Statement (P&L) ($ in thousands)

9/30/2022
12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
Revenues   5597371
Other income   5597371
Gross profit:   5597371
Operating expenses(36,063)(36,307)(36,194)(29,544)(20,658)(17,249)
Other undisclosed operating income 365  390406
Operating loss:(36,063)(36,307)(36,194)(28,985)(20,195)(16,772)
Nonoperating income771,8891,677926546 
Investment income, nonoperating(30)1,6481,685888546 
Other nonoperating income (expense)107 (8)39  
Interest and debt expense   (1,200) (291)
Loss from continuing operations before equity method investments, income taxes:(35,986)(34,418)(34,517)(29,259)(19,650)(17,063)
Other undisclosed loss from continuing operations before income taxes (3,302) (997)  
Loss before gain (loss) on sale of properties:(35,986)(37,720)(34,517)(30,255)(19,650)(17,063)
Other undisclosed net income (loss)72,687(272)    
Net income (loss):36,701(37,992)(34,517)(30,255)(19,650)(17,063)
Other undisclosed net income (loss) attributable to parent(73,401)785(1,844) (2,485)(14,774)
Net loss attributable to parent:(36,701)(37,207)(36,361)(30,255)(22,135)(31,837)
Other undisclosed net loss available to common stockholders, basic(929)(265)(351)(22) (14)
Net loss available to common stockholders, basic:(37,630)(37,472)(36,712)(30,277)(22,135)(31,852)
Other undisclosed net loss available to common stockholders, diluted (1,108)(1,086)   
Net loss available to common stockholders, diluted:(37,630)(38,580)(37,798)(30,277)(22,135)(31,852)

Comprehensive Income ($ in thousands)

9/30/2022
12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
Net income (loss):36,701(37,992)(34,517)(30,255)(19,650)(17,063)
Comprehensive income (loss), net of tax, attributable to parent:36,701(37,992)(34,517)(30,255)(19,650)(17,063)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: